Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046100 | 0.83 | KCNN4 (0.50) | KCNN4MAPK1KMT2AMAPTPPARG | |
| SCHEMBL22722985 | 0.83 | KCNN4 (0.50) | KCNN4MAPK1KMT2AMAPTPPARG | |
| SCHEMBL2517938 | 0.83 | KCNN4 (0.50) | KCNN4MAPK1KMT2AMAPTPPARG | |
| Quinoline SCHEMBL27818687 | 0.82 | ALDH1A1 (0.46) | KMT2APPARGPPARAALDH1A1ALOX15 | |
| SCHEMBL27785391 | 0.81 | PPARA (0.44) | KCNN4MAPK1KMT2AMAPTPPARG | |
| SCHEMBL891406 | 0.79 | ALDH1A1 (0.56) | KCNN4MAPK1KMT2AMAPTPPARG | |
| SCHEMBL3128240 | 0.78 | MAPT (0.50) | KCNN4MAPK1KMT2AMAPTPPARG | |
| SCHEMBL8694822 | 0.77 | ALDH1A1 (0.44) | MAPK1KMT2AMAPTPPARGPPARA | |
| SCHEMBL5691818 | 0.76 | PPARG (0.61) | KCNN4MAPK1KMT2AMAPTPPARG | |
| SCHEMBL5322361 | 0.76 | CYP2C19 (0.47) | KCNN4MAPK1KMT2AMAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| US-10314853-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2012-01-26 | — | — | US | disclosed |
| US-20110287059-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2011-11-24 | — | — | US | disclosed |
| EP-2367444-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368111-A1 | HONEY ANALYSIS | Comvita New Zealand Limited (NZ) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010082845-A1 | HONEY ANALYSIS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010082846-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | COMVITA NEW ZEALAND LIMITED (NZ) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021061-A1 | MEDICAL AND NUTRITIONAL FORMULATIONS | FABP6, NNT, IAPP | KCNN4 1932/4885MAPK1 3386/4885KMT2A 3315/4885 |
| US-20110287059-A1 | HONEY ANALYSIS | GLO1, GLMN, AGER | KCNN4 1306/4885MAPK1 3482/4885KMT2A 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.